These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 30873381)
1. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas. Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ Front Oncol; 2019; 9():92. PubMed ID: 30873381 [TBL] [Abstract][Full Text] [Related]
2. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307 [TBL] [Abstract][Full Text] [Related]
4. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162 [TBL] [Abstract][Full Text] [Related]
5. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309 [TBL] [Abstract][Full Text] [Related]
6. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas. Lu VM; Daniels DJ Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139 [TBL] [Abstract][Full Text] [Related]
8. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG. Nikolaev A; Fiveash JB; Yang ES Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975 [TBL] [Abstract][Full Text] [Related]
9. Genomic Insights into Diffuse Intrinsic Pontine Glioma. Lapin DH; Tsoli M; Ziegler DS Front Oncol; 2017; 7():57. PubMed ID: 28401062 [TBL] [Abstract][Full Text] [Related]
10. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018 [TBL] [Abstract][Full Text] [Related]
19. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care. Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081 [TBL] [Abstract][Full Text] [Related]
20. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]